Absolutely amazing presentation.
Without a doubt headed in the right direction.
Highly motivated, highly intelligent, with already very promising phase and pre-phase data on the table.
\------------------------------------------
They are developing a single drug (LAM-001) and delivery method that will possibly accompany and address unmet needs of those who've undergone lung transplant.
As well, treat severe respiratory distress along side existing treatments.
One drug, 3 directions..
With the most needed (in my opinion) being with post transplant treatment of (BOS - 28k addressable patients)
Essentially, there is zero options for those with declined lung function, post transplant with LAM-001 actually showing reversal of (BOS).
They are also addressing complimentary treatment for PH-ILD (206k addressable patients) and SAPH (60k addressable patients), within the inhaled (Rapamycin; LAM-001) via mTOR receptor delivery.
With a vocal unmet need for over a decade by top transplant surgeons, Quince Therapeutics, alongside Orphai Therapeutics, have found a promising treatment for these severe life threatening and debilitating conditions.
\--------------------------------------------
Operational runway until 2028, phase data expected all along 2027 and 2028.
Current share price - $30.32 - 1yr target $77.20
My holdings - 205 shares at above current price.
Have a listen! 👏 👏 👏 💯
https://ir.quincetx. com/events